WO2010142678A3 - Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide - Google Patents

Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide Download PDF

Info

Publication number
WO2010142678A3
WO2010142678A3 PCT/EP2010/058006 EP2010058006W WO2010142678A3 WO 2010142678 A3 WO2010142678 A3 WO 2010142678A3 EP 2010058006 W EP2010058006 W EP 2010058006W WO 2010142678 A3 WO2010142678 A3 WO 2010142678A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbamoylamino
polymorphs
carboxamide
phenoxy
trifluoromethyl
Prior art date
Application number
PCT/EP2010/058006
Other languages
French (fr)
Other versions
WO2010142678A2 (en
Inventor
Ramesh Matioram Gidwani
Vikas S Wakchaure
Hans-Günter Striegel
Wolfgang Albrecht
Original Assignee
Ratiopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm Gmbh filed Critical Ratiopharm Gmbh
Priority to EP10722711.8A priority Critical patent/EP2440531A2/en
Publication of WO2010142678A2 publication Critical patent/WO2010142678A2/en
Publication of WO2010142678A3 publication Critical patent/WO2010142678A3/en
Priority to IL216649A priority patent/IL216649A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present invention relates to polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]- carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide and pharmaceutical compositions comprising the same.
PCT/EP2010/058006 2009-06-12 2010-06-08 Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide WO2010142678A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP10722711.8A EP2440531A2 (en) 2009-06-12 2010-06-08 Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide
IL216649A IL216649A0 (en) 2009-06-12 2011-11-28 Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1395CH2009 2009-06-12
IN1395/CHE/2009 2009-06-12

Publications (2)

Publication Number Publication Date
WO2010142678A2 WO2010142678A2 (en) 2010-12-16
WO2010142678A3 true WO2010142678A3 (en) 2011-03-24

Family

ID=42931997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/058006 WO2010142678A2 (en) 2009-06-12 2010-06-08 Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide

Country Status (3)

Country Link
EP (1) EP2440531A2 (en)
IL (1) IL216649A0 (en)
WO (1) WO2010142678A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2480535A1 (en) * 2009-09-24 2012-08-01 Ranbaxy Laboratories Limited Polymorphs of sorafenib acid addition salts
WO2012071425A1 (en) 2010-11-22 2012-05-31 Teva Pharmaceutical Industries Ltd. Solid state forms of sorafenib besylate, and processes for preparations thereof
WO2013175506A2 (en) * 2012-05-21 2013-11-28 Hetero Research Foundation Process for sorafenib tosylate polymorph iii
EP2922820A4 (en) * 2012-05-23 2016-06-01 Shilpa Medicare Ltd Process for preparing crystalline sorafenib tosylate
CN103570613B (en) * 2012-07-18 2016-06-15 苏州泽璟生物制药有限公司 The polymorphic form of deuterated ω-diphenyl urea or its salt
CN106336377A (en) * 2015-07-17 2017-01-18 苏州亚宝药物研发有限公司 Preparation method for crystal form II of sorafenib tosylate
CN108368052A (en) * 2015-12-14 2018-08-03 正大天晴药业集团股份有限公司 Half Sorafenib Tosylate hydrate crystallization and preparation method thereof
CN107759517A (en) * 2016-08-23 2018-03-06 广州白云山医药集团股份有限公司白云山制药总厂 A kind of preparation method of Sorafenib Tosylate crystal formation I
RU2766288C2 (en) * 2020-03-30 2022-03-11 Общество с ограниченной ответственностью "АКСЕЛЬФАРМ" Amorphous form of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)-amino]phenoxy}-n-methylpyridine-2-carboxamide tosylate (versions), method for production and use thereof for treatment of oncological diseases

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026501A1 (en) * 2004-08-27 2006-03-09 Bayer Pharmaceuticals Corporation New pharmaceutical compositions for the treatment of cancer
WO2006034797A1 (en) * 2004-09-29 2006-04-06 Bayer Healthcare Ag Thermodynamically stable form of bay 43-9006 tosylate
WO2006094626A1 (en) * 2005-03-07 2006-09-14 Bayer Healthcare Ag Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer
WO2007038524A2 (en) * 2005-09-28 2007-04-05 Ssci, Inc. Cocrystallization methods
WO2008008733A2 (en) * 2006-07-10 2008-01-17 Elan Pharma International Ltd. Nanoparticulate sorafenib formulations
WO2009106825A1 (en) * 2008-02-27 2009-09-03 Cipla Limited Polymorphs of sorafenib and salts thereof
CN101584661A (en) * 2009-06-10 2009-11-25 北京大学 Preparation of sorafenib self-microemulsifying drug delivery system for oral administration or intravenous injection and use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026501A1 (en) * 2004-08-27 2006-03-09 Bayer Pharmaceuticals Corporation New pharmaceutical compositions for the treatment of cancer
WO2006034797A1 (en) * 2004-09-29 2006-04-06 Bayer Healthcare Ag Thermodynamically stable form of bay 43-9006 tosylate
WO2006094626A1 (en) * 2005-03-07 2006-09-14 Bayer Healthcare Ag Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer
WO2007038524A2 (en) * 2005-09-28 2007-04-05 Ssci, Inc. Cocrystallization methods
WO2008008733A2 (en) * 2006-07-10 2008-01-17 Elan Pharma International Ltd. Nanoparticulate sorafenib formulations
WO2009106825A1 (en) * 2008-02-27 2009-09-03 Cipla Limited Polymorphs of sorafenib and salts thereof
CN101584661A (en) * 2009-06-10 2009-11-25 北京大学 Preparation of sorafenib self-microemulsifying drug delivery system for oral administration or intravenous injection and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2009, WANG, XUEQING ET AL: "Sorafenib self-microemulsifying drug delivery system for oral medication or intravenous injection, and the preparation method and application thereof", XP002613940, retrieved from STN Database accession no. 2009:1482361 *
PETIT S ET AL: "The Amorphous State", 1 January 2006, 20060101, PAGE(S) 259 - 285, ISBN: 978-3-527-31146-0, XP002481458 *

Also Published As

Publication number Publication date
WO2010142678A2 (en) 2010-12-16
IL216649A0 (en) 2012-02-29
EP2440531A2 (en) 2012-04-18

Similar Documents

Publication Publication Date Title
WO2010142678A3 (en) Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
IL194850A (en) Benzoazepin-oxy-acetic acid derivatives as ppar-delta agonists used for the increase of hdl-c, lower ldl-c and lower cholesterol and pharmaceutical compositions comprising same
IL233677A (en) Substituted benzisoxazole aminopyrazolo-pyrimidine compounds, pharmaceutical compositions comprising them and use of the compounds for the manufacture of medicaments
WO2011077043A3 (en) Phenol derivatives and pharmaceutical or cosmetic use thereof
IL224288A (en) Derivatives of substituted pyrazolamide, pharmaceutical compositions comprising the same and uses thereof
WO2008127646A8 (en) Transaminase-based processes for preparation of pregabalin
WO2012042371A3 (en) Pharmaceutical composition
JO3021B1 (en) 4-[4-({[ 4- chloro-3- (trifluoromethyl) phenyl] carbamoyl}lamino)-3- fluoromethyl]-N-methylpyridine -2- carboxamide monohydrate
AU2011243597A1 (en) Novel hydroxamic acid derivative
WO2010030983A3 (en) Pyrazole carboxamide inhibitors of factor xa
WO2012065057A3 (en) Phosphatidylinositol 3-kinase inhibitors and methods of their use
WO2010118291A3 (en) Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
WO2010141693A3 (en) Borinic compositions
HRP20171742T1 (en) Composition of 2,4,6-trifluoro-n-6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
SI2470166T1 (en) New compositions of 1-š2-(2,4-dimethyl-phenylsulfanyl)-phenylćpiperazine
WO2009115084A3 (en) Pyrrolopyrimidine derivatives, and use thereof
IL209360A (en) Pharmaceutical compositions comprising pm00104 for the treatment of multiple myeloma
IL220586A (en) Carboxamide compound, pharmaceutical composition comprising same and use thereof
WO2009125409A3 (en) Fatty acid amides and uses thereof
WO2011088160A3 (en) Novel cyp17 inhibitors
EP2504331A4 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
WO2010025370A3 (en) Preparation of ranolazine
WO2012075015A3 (en) Oral metronidazole pharmaceutical compositions
IL215153A0 (en) Amide derivative compounds, compositions comprising the same and uses there of

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10722711

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010722711

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE